IRIS Accounts Production v25.2.0.378 07569193 director 1.4.23 31.3.24 31.3.24 9.9.25 false true true false false true false Auditors Opinion iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 07569193 2023-03-31 07569193 2024-03-31 07569193 2023-04-01 2024-03-31 07569193 2022-03-31 07569193 2022-04-01 2023-03-31 07569193 2023-03-31 07569193 ns15:EnglandWales 2023-04-01 2024-03-31 07569193 ns14:PoundSterling 2023-04-01 2024-03-31 07569193 ns10:Director1 2023-04-01 2024-03-31 07569193 ns10:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 07569193 ns10:SmallEntities 2023-04-01 2024-03-31 07569193 ns10:Audited 2023-04-01 2024-03-31 07569193 ns10:SmallCompaniesRegimeForDirectorsReport 2023-04-01 2024-03-31 07569193 ns10:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 07569193 ns10:FullAccounts 2023-04-01 2024-03-31 07569193 ns10:RegisteredOffice 2023-04-01 2024-03-31 07569193 ns5:CurrentFinancialInstruments 2024-03-31 07569193 ns5:CurrentFinancialInstruments 2023-03-31 07569193 ns5:ShareCapital 2024-03-31 07569193 ns5:ShareCapital 2023-03-31 07569193 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 07569193 ns5:RetainedEarningsAccumulatedLosses 2023-03-31 07569193 ns5:LeaseholdImprovements 2023-03-31 07569193 ns5:FurnitureFittings 2023-03-31 07569193 ns5:MotorVehicles 2023-03-31 07569193 ns5:ComputerEquipment 2023-03-31 07569193 ns5:LeaseholdImprovements 2023-04-01 2024-03-31 07569193 ns5:FurnitureFittings 2023-04-01 2024-03-31 07569193 ns5:MotorVehicles 2023-04-01 2024-03-31 07569193 ns5:ComputerEquipment 2023-04-01 2024-03-31 07569193 ns5:LeaseholdImprovements 2024-03-31 07569193 ns5:FurnitureFittings 2024-03-31 07569193 ns5:MotorVehicles 2024-03-31 07569193 ns5:ComputerEquipment 2024-03-31 07569193 ns5:LeaseholdImprovements 2023-03-31 07569193 ns5:FurnitureFittings 2023-03-31 07569193 ns5:MotorVehicles 2023-03-31 07569193 ns5:ComputerEquipment 2023-03-31 07569193 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-03-31 07569193 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2023-03-31

REGISTERED NUMBER: 07569193 (England and Wales)

IMPERIAL BIO DISCOVERY LTD

Report of the Director and

Financial Statements for the Year Ended 31 March 2024

| IMPERIAL BIO DISCOVERY LTD (Registered number: 07569193) |

Contents of the Financial Statements

for the Year Ended 31 March 2024

Page |

Company Information | 1 |

Report of the Director | 2 |

Balance Sheet | 4 |

Notes to the Financial Statements | 5 |

| IMPERIAL BIO DISCOVERY LTD |

Company Information

for the Year Ended 31 March 2024

| DIRECTOR: | Mr Jaspal Singh Kooner

| REGISTERED OFFICE: | Unit 1, Manhattan Business Park

| Westgate, Ealing, London

| W5 1UP

| REGISTERED NUMBER: | 07569193 (England and Wales)

| AUDITORS: | DSJ Partners (UK) Limited

| 2nd Floor

| 1 Bell Street

| London

| NW1 5BY

| IMPERIAL BIO DISCOVERY LTD (Registered number: 07569193) |

Report of the Director

for the Year Ended 31 March 2024

The director presents his report with the financial statements of the company for the year ended 31 March 2024.

PRINCIPAL ACTIVITY

The principal activity of the company in the year under review was that of providing storage facilities to healthcare industry.

DIRECTOR

Mr Jaspal Singh Kooner held office during the whole of the period from 1 April 2023 to the date of this report.

GOING CONCERN

The shareholders of the parent company have provided confirmation to the director that they will continue to support the company for a period of at least 12 months from the date on which the financial statements are approved. The director is therefore satisfied that the company will have sufficient funds to meet its liabilities as they fall due and have therefore prepared the financial statements on a going concern basis.

STATEMENT OF DIRECTOR'S RESPONSIBILITIES

The director is responsible for preparing the Report of the Director and the financial statements in accordance with applicable law and regulations.

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to:

- | select suitable accounting policies and then apply them consistently;

- | make judgements and accounting estimates that are reasonable and prudent;

- | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the director is aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS

The auditors, DSJ Partners (UK) Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

| IMPERIAL BIO DISCOVERY LTD (Registered number: 07569193) |

Report of the Director

for the Year Ended 31 March 2024

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

Mr Jaspal Singh Kooner - Director

9 September 2025

| IMPERIAL BIO DISCOVERY LTD (Registered number: 07569193) |

Balance Sheet

31 March 2024

| 2024 |  | 2023

| Notes | £ | £ |

FIXED ASSETS

Tangible assets | 4 | 137,292 |  | 157,634 |  |

CURRENT ASSETS

Debtors | 5 | 430,394 |  | 79,304 |  |

Cash at bank | 7,860 |  | - |  |

438,254 |  | 79,304 |  |

CREDITORS

Amounts falling due within one year | 6 | (534,352 | ) | (455,718 | ) |

NET CURRENT LIABILITIES | (96,098 | ) | (376,414 | ) |

TOTAL ASSETS LESS CURRENT LIABILITIES | 41,194 |  | (218,780 | ) |

CAPITAL AND RESERVES

Called up share capital | 100 |  | 100 |  |

Retained earnings | 41,094 |  | (218,880 | ) |

41,194 |  | (218,780 | ) |

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 9 September 2025 and were signed by:

Mr Jaspal Singh Kooner - Director

| IMPERIAL BIO DISCOVERY LTD (Registered number: 07569193) |

Notes to the Financial Statements

for the Year Ended 31 March 2024

1. | STATUTORY INFORMATION

| IMPERIAL BIO DISCOVERY LTD is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

| Going concern

| The shareholders of the parent company have provided confirmation to the director that they will continue to support the company for a period of at least 12 months from the date on which the financial statements are approved. The director is therefore satisfied that the company will have sufficient funds to meet its liabilities as they fall due and have therefore prepared the financial statements on a going concern basis.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Tangible fixed assets

| Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

| Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method and the reducing balance method.

| Depreciation is provided on the following basis:

| Short-term leasehold property - 2% Straight line

| Motor vehicles - 20% Reducing balance

| Fixtures and fittings - 15% Reducing balance

| Computer equipment - 25% Straight line

| The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

| Gains and losses on disposals are determined by comparing the proceeds with the carrying amount

| and are recognised in profit or loss.

| IMPERIAL BIO DISCOVERY LTD (Registered number: 07569193) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2024

2. | ACCOUNTING POLICIES - continued

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Foreign currency translation

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Debtors

| Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

| Cash and cash equivalents

| Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

| Creditors

| Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

| Financial instruments

| The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 1 (2023 - 2 ) .

| IMPERIAL BIO DISCOVERY LTD (Registered number: 07569193) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2024

4. | TANGIBLE FIXED ASSETS

| Improvements |  | Fixtures |

| to |  | and |  | Motor |  | Computer |

| property |  | fittings |  | vehicles |  | equipment |  | Totals

£ | £ | £ | £ | £ |

| COST

| At 1 April 2023 | 141,132 |  | 86,286 |  | 60,500 |  | 649 |  | 288,567 |  |

| Disposals | - |  | - |  | (60,500 | ) | - |  | (60,500 | ) |

| At 31 March 2024 | 141,132 |  | 86,286 |  | - |  | 649 |  | 228,067 |  |

| DEPRECIATION

| At 1 April 2023 | 28,394 |  | 54,078 |  | 47,812 |  | 649 |  | 130,933 |  |

| Charge for year | 2,823 |  | 4,831 |  | - |  | - |  | 7,654 |  |

| Eliminated on disposal | - |  | - |  | (47,812 | ) | - |  | (47,812 | ) |

| At 31 March 2024 | 31,217 |  | 58,909 |  | - |  | 649 |  | 90,775 |  |

| NET BOOK VALUE

| At 31 March 2024 | 109,915 |  | 27,377 |  | - |  | - |  | 137,292 |  |

| At 31 March 2023 | 112,738 |  | 32,208 |  | 12,688 |  | - |  | 157,634 |  |

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2024 | 2023 |

£ | £ |

| Trade debtors | 4,036 |  | - |  |

| Other debtors | 426,358 |  | 79,304 |  |

430,394 |  | 79,304 |  |

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2024 | 2023 |

£ | £ |

| Due to group undertakings | 344,019 |  | 297,445 |  |

| Trade creditors | 113,998 |  | 125,944 |  |

| Other creditors | 76,335 |  | 32,329 |  |

534,352 |  | 455,718 |  |

7. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

| The Report of the Auditors was unqualified.

| Bharat Kumar Dhanani (Senior Statutory Auditor)

| for and on behalf of DSJ Partners (UK) Limited

| IMPERIAL BIO DISCOVERY LTD (Registered number: 07569193) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2024

8. | RELATED PARTY DISCLOSURES

| During the year, the director has provided working capital loan to the company. The loan is non- interest bearing and repayable on demand. At the balance sheet date, amount repayable to the directors was £73,335 (2023: £Nil).

| During the year, the company has received working capital loan of £46,047 from a fellow group company, London Heart Clinic Limited. The loan is non-interest bearing and repayable on demand. At the balance sheet date amount repayable to this company was £292,156 (2023:£246,109).

| During the year, the company has received working capital loan of £528 from a fellow group company, Golden Manor Healthcare (Ealing) Limited. The loan is non-interest bearing and repayable on demand. At the balance sheet date amount repayable to this company was £12,102 (2023:£11,574).

| At the year end, amount repayable to fellow group company, Ealing Paces MRCP Limited was £39,762 (2023:£39,762). The loan is non-interest bearing and repayable on demand.

9. | ULTIMATE CONTROLLING PARTY

| The controlling party is Mr Jaspal Singh Kooner.

| The company's immediate and ultimate parent company is 57 AG Limited which is registered in England and Wales and for which group financial statements are prepared. Copies of the group financial statements are available from Companies House, Crown Way, Cardiff, CF14 3UZ.